Cite
SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
MLA
Fan, Lei, et al. “SHC014748M, a Novel Selective Inhi-Bitor of PI3Kδ, Demonstrates Promising Preclinical Antitumor Activity in B Cell Lymphomas and Chronic Lymphocytic Leukemia.” Neoplasia, vol. 22, no. 12, Dec. 2020, pp. 714–24. EBSCOhost, https://doi.org/10.1016/j.neo.2020.10.004.
APA
Fan, L., Wang, C., Zhao, L., Wang, Z., Zhang, X., Liu, X., Cao, L., Xu, W., & Li, J. (2020). SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Neoplasia, 22(12), 714–724. https://doi.org/10.1016/j.neo.2020.10.004
Chicago
Fan, Lei, Chao Wang, Liwen Zhao, Zhiqiang Wang, Xian Zhang, Xiaorong Liu, Lei Cao, Wei Xu, and Jianyong Li. 2020. “SHC014748M, a Novel Selective Inhi-Bitor of PI3Kδ, Demonstrates Promising Preclinical Antitumor Activity in B Cell Lymphomas and Chronic Lymphocytic Leukemia.” Neoplasia 22 (12): 714–24. doi:10.1016/j.neo.2020.10.004.